




RealRate

PHARMACEUTICAL 2020

Pacira BioSciences Inc.
Rank 169 of 358





RealRate

PHARMACEUTICAL 2020

Pacira BioSciences Inc.
Rank 169 of 358



The relative strengths and weaknesses of Pacira BioSciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pacira BioSciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Pacira BioSciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 100% points.

The company's Economic Capital Ratio, given in the ranking table, is 92%, being 55% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	408,557
Cost of Goods Sold	106,712
Intangible Assets	203,934
Liabilities, Current	107,673
Liabilities, Non-Current	42,440
Other Assets	113,893
Other Compr. Net Income	602
Other Expenses	31,201
Other Liabilities	326,008
Other Net Income	-21,228
Other Revenues	421,026
Property and Equipment	104,681
Research and Development	72,119
Selling, General and Administrative Expense	200,782

Output Variable	Value in 1000 USD
Assets	831,065
Liabilities	476,121
Expenses	410,814
Revenues	421,026
Stockholders Equity	354,944
Net Income	-11,016
Comprehensive Net Income	-10,715
Economic Capital Ratio	92%